浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Network meta-analysis for efficacy and safety of TACE combined with anti-angiogenic drugs in the treatment of unresectable primary liver cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 20, Pages: 2533-2540(2024)
- 作者机构：
1.北京中医药大学深圳医院，广东 深圳 518172
2.北京中医药大学，北京 100029
3.陕西双博中医肝肾病医院肾病科，西安 710016
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.20.16
CLC： R735.7;R979.1Published：30 October 2024，
Received：31 May 2024，
Revised：05 July 2024，
- 稿件说明：
移动端阅览
卢芬萍,邢光艳,刘博文等.TACE联合抗血管生成药治疗不可切除PLC有效性和安全性的网状Meta分析 Δ[J].中国药房,2024,35(20):2533-2540.
LU Fenping,XING Guangyan,LIU Bowen,et al.Network meta-analysis for efficacy and safety of TACE combined with anti-angiogenic drugs in the treatment of unresectable primary liver cancer[J].ZHONGGUO YAOFANG,2024,35(20):2533-2540.
卢芬萍,邢光艳,刘博文等.TACE联合抗血管生成药治疗不可切除PLC有效性和安全性的网状Meta分析 Δ[J].中国药房,2024,35(20):2533-2540. DOI： 10.6039/j.issn.1001-0408.2024.20.16.
LU Fenping,XING Guangyan,LIU Bowen,et al.Network meta-analysis for efficacy and safety of TACE combined with anti-angiogenic drugs in the treatment of unresectable primary liver cancer[J].ZHONGGUO YAOFANG,2024,35(20):2533-2540. DOI： 10.6039/j.issn.1001-0408.2024.20.16.
摘要
目的
2
系统评价经动脉化疗栓塞术（TACE）联合抗血管生成药治疗不可切除原发性肝癌（PLC）的有效性和安全性。
方法
2
检索中国知网、the Cochrane Library等中英文数据库和Google、百度学术，收集TACE联合抗血管生成药治疗不可切除PLC的随机对照试验（RCT），检索时限均为建库至2024年5月27日。筛选文献、提取资料、评价文献质量后，采用R 4.2.2和Stata 17.0软件进行网状Meta分析。
结果
2
共纳入44项RCT，共计5 607例患者，涉及8种干预措施。网状Meta分析结果显示，在延长中位总生存期（mOS）、中位无进展生存期（mPFS）方面，以TACE+阿帕替尼疗效最优，网状Meta排序前2位的为TACE+阿帕替尼、TACE+索拉非尼；在提高客观缓解率（ORR）和疾病控制率（DCR）方面，以TACE+多纳非尼疗效最优，网状Meta排序前2位的为TACE+多纳非尼、TACE+仑伐替尼；安全性方面，以TACE+多纳非尼最优，网状Meta排序前2位的为TACE+多纳非尼、TACE+阿帕替尼。
结论
2
TACE+阿帕替尼、TACE+多纳非尼用于不可切除PLC患者的疗效均较好，且以TACE+多纳非尼的安全性最优。
Abstract
OBJECTIVE
2
To systematically evaluate the efficacy and safety of transcatheter arterial chemoembolization （TACE） combined with anti-angiogenic drugs for the treatment of unresectable primary liver cancer （PLC）.
METHODS
2
Retrieved from Chinese and English databases such as CNKI， the Cochrane Library， Google， and Baidu Academic， randomized controlled trial （RCT） about TACE combined with anti-angiogenic drugs for the treatment of unresectable PLC were collected from the inception to May 27， 2024. After screening the literature， extracting data， and evaluating the quality of the literature， network meta-analysis was performed using R 4.2.2 and Stata 17.0.
RESULTS
2
A total of 44 RCT were included， involving 5 607 patients and 8 interventions. The network meta-analysis results showed that for prolonging median overall survival （mOS） and median progression-free survival （mPFS）， TACE+apatinib had the best efficacy， with TACE+apatinib and TACE+sorafenib ranking as the top two. For improving objective response rate （ORR） and disease control rate （DCR）， TACE+donafenib had the best efficacy， with TACE+donafenib and TACE+ lenvatinib ranking as the top two. In terms of safety， TACE+donafenib was the best， with TACE+donafenib and TACE+apatinib ranking as the top two.
CONCLUSIONS
2
TACE+apatinib and TACE+donafenib have good efficacy for patients with unresectable PLC， and TACE+donafenib has the best safety profile.
关键词
原发性肝癌不可切除经动脉化疗栓塞术抗血管生成药TACE网状Meta分析
Keywords
unresectabletranscatheter arterial chemoembolizationanti-angiogenic drugsTACEnetwork meta-analysis
references
RUMGAY H，ARNOLD M，FERLAY J，et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol，2022，77（6）：1598-1606.
国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南：2024年版[J]. 中华外科杂志，2024，62（6）：477-503.
Medical Administration and Management Bureau，National Health Commission.Guidelines for diagnosis and treatment of primary liver cancer：2024 edition[J]. Chin J Surg，2024，62（6）：477-503.
PARK J W，CHEN M S，COLOMBO M，et al. Global patterns of hepatocellular carcinoma management from diagnosis to death：the BRIDGE study[J]. Liver Int，2015，35（9）：2155-2166.
CHANG Y，JEONG S W，YOUNG JANG J，et al. Recent updates of transarterial chemoembolization in hepatocellular carcinoma[J]. Int J Mol Sci，2020，21（21）：8165.
CHOI G H，JANG E S，KIM J W，et al. Prognostic role of plasma level of angiopoietin-1，angiopoietin-2，and vascular endothelial growth factor in hepatocellular carcinoma[J]. World J Gastroenterol，2021，27（27）：4453-4467.
HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ，2011，343：d5928.
莫嘉浩，綦向军，许洪彬，等.中药注射液治疗慢性肾功能不全的贝叶斯网状Meta分析[J].中国中药杂志，2021，46（2）：454-466.
MO J H，QI X J，XU H B，et al. Bayesian network meta-analysis of traditional Chinese medicine injection in the treatment of chronic renal insufficiency [J]. China J Chin Mat Med，2021，46（2）：454-466.
MEYER T，FOX R，MA Y T，et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma（TACE 2）：a randomised placebo-controlled，double-blind，phase 3 trial[J]. Lancet Gastroenterol Hepatol，2017，2（8）：565-575.
KUDO M，UESHIMA K，IKEDA M，et al. Final results of TACTICS：a randomized，prospective trial comparing transar-terial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma[J]. Liver Cancer，2022，11（4）：354-367.
KUDO M，IMANAKA K，CHIDA N，et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer，2011，47（14）：2117-2127.
HOFFMANN K，GANTEN T，GOTTHARDTP D，et al. Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients：a prospective，randomized，double-blind，phase Ⅲ trial[J]. BMC Cancer，2015，15：392.
朱九荣，岳恺，叶亚平，等. 甲苯磺酸索拉非尼联合TACE术用于不可手术切除的局限性肝癌患者治疗的效果分析[J]. 实用癌症杂志，2024，39（4）：648-651，677.
ZHU J R，YUE K，YE Y P，et al. Efficacy analysis of sorafenib tosylate combined with TACE in the treatment of unresectable localized liver cancer patients[J]. Pract J Cancer，2024，39（4）：648-651，677.
池希，张佳光.索拉非尼联合经皮肝动脉化疗栓塞术治疗原发性肝癌临床效果分析[J].中国社区医师，2022，38（22）：16-18.
CHI X，ZHANG J G.Clinical effect analysis of sorafenib combined with transarterial chemoembolization in treatment of primary liver cancer[J]. Chin Comm Doct，2022，38（22）：16-18.
顾雅雯. 索拉非尼+TACE治疗在肝细胞性肝癌患者的应用效果分析[J/OL]. 临床医药文献电子杂志，2019，6（A3）：21-22[2024-05-31].https：//kns.cnki.net/kcms2/article/abstract?v=WNLjQhMUSxIkmqiAt0NHJpS3Ilyao-ARDQxBNfXuO17KYDYU_7Z2UbKxNEunOhDwKd64-hs5ProONNE2FxQUgiOEFGFWV07nndfrwTp5OZk9Y7Nk-YcmdbZtZKIgpfHljDW7xhNtVMT4g_aMvaTOALpdm0-uKS38netDCgvbp_UnV0yh1bIWvlgAjhgFMoEC78buo4db_Wsz4WtFYZrclBFKhfjTiQaXjfY&uniplatform=NZKPT& language=CHS.DOI：10.16281/j.cnki.jocml.2019.a3.010https://kns.cnki.net/kcms2/article/abstract?v=WNLjQhMUSxIkmqiAt0NHJpS3Ilyao-ARDQxBNfXuO17KYDYU_7Z2UbKxNEunOhDwKd64-hs5ProONNE2FxQUgiOEFGFWV07nndfrwTp5OZk9Y7Nk-YcmdbZtZKIgpfHljDW7xhNtVMT4g_aMvaTOALpdm0-uKS38netDCgvbp_UnV0yh1bIWvlgAjhgFMoEC78buo4db_Wsz4WtFYZrclBFKhfjTiQaXjfY&uniplatform=NZKPT&language=CHS.DOI:10.16281/j.cnki.jocml.2019.a3.010.
GU Y W.Analysis of the effect of sorafenib + TACE in the treatment of HCC[J/OL].Electron J Clin Med Literat，2019，6（A3）：21-22[2024-05-31].https：//kns.cnki.net/kcms2/article/abstract?vhttps://kns.cnki.net/kcms2/article/abstract?v＝WNLjQhMUSxIkmqiAt0NHJpS3Ilyao-ARDQxBNfXuO17KYDYU_7Z2UbKxNEunOhDwKd64-hs5ProONNE2FxQUgiOEFGFWV07nndfrwTp5OZk9Y7Nk-YcmdbZtZKIgpfHljDW7xhNtVMT4g_aMvaTOALpdm0-uKS38netDCgvbp_UnV0yh1bIWvlgAjhgFMoEC78buo4db_Wsz4language=CHSWtFYZrclBFKhfjTiQaXjfY&uniplatform=NZKPT&.DOI：10.16281/j.cnki.jocml.2019.a3.010http://dx.doi.org/10.16281/j.cnki.jocml.2019.a3.010.
周松强，游燊，王耀东.索拉非尼联合肝动脉化疗栓塞术治疗晚期肝癌的临床疗效及安全性[J].临床合理用药杂志，2018，11（36）：47-48.
ZHOU S Q，YOU S，WANG Y D. The clinical efficacy and safety of sorafenib combined with transarterial chemoem-bolization in the treatment of advanced liver cancer[J]. Chin J Clin Rat Drug Use，2018，11（36）：47-48.
易文城. 索拉非尼辅助治疗中晚期肝细胞癌的可行性及安全性[J]. 海峡药学，2018，30（12）：92-93.
YI W C.Feasibility and safety of sorafenib in adjuvant treatment of advanced hepatocellular carcinoma[J]. Strait Pharm J，2018，30（12）：92-93.
游志坚，郑锐年，胡夏荣，等. 经导管肝动脉化疗栓塞联合索拉非尼治疗不能手术切除肝细胞肝癌的疗效[J]. 中国肿瘤临床与康复，2015，22（10）：1212-1214.
YOU Z J，ZHENG R N，HU X R，et al. Curative efficacy of transcatheter arterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma[J]. Chin J Clin Oncol Rehabil，2015，22（10）：1212-1214.
谭勇，张涛，彭晶晶，等. 索拉非尼联合经动脉化疗栓塞治疗原发性大肝癌的疗效[J]. 西南国防医药，2015，25（4）：386-389.
TAN Y，ZHANG T，PENG J J，et al. Curative effect of sorafenib combined with transcatheter arterial chemoembolization in treatment of large primary liver cancer[J]. Med J Natl Defending Forces Southwest China，2015，25（4）：386-389.
孙恒，韩文杰. TACE联合索拉非尼对不能手术切除肝细胞肝癌的疗效分析[J]. 胃肠病学和肝病学杂志，2014，23（5）：486-488.
SUN H，HAN W J. Analysis of curative effect of transcatheter arterial chemoembolization combined with sorafenib for not operation resection of hepatocellular carcinoma[J]. Chin J Gastroenterol Hepatol，2014，23（5）：486-488.
周仁贵，周锡建，李相勇，等. 索拉非尼联合化疗栓塞治疗晚期原发性肝癌的疗效分析[J]. 现代生物医学进展，2014，14（13）：2494-2496.
ZHOU R G，ZHOU X J，LI X Y，et al. Clinical effects of sorafenib combined with transcatheter arterial chemoembolization on the treatment of advanced primary hepatocellular carcinoma[J]. Prog Mod Biomed，2014，14（13）：2494-2496.
XU Q，HUANG Y H，SHI H J，et al. Sunitinib versus sorafenib plus transarterial chemoembolization for inopera-ble hepatocellular carcinoma patients[J]. J BUON，2018，23（1）：193-199.
LIU J F，XIE S S，DUAN X H，et al. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma[J]. Cancer Chemother Pharmacol，2020，85（1）：69-76.
ZHU Y X，FENG B，MEI L，et al. Clinical efficacy of TACE combined with apatinib in the treatment of advanced hepatocellular carcinoma[J]. J BUON，2019，24（2）：608-614.
CHEN C，DUAN X T，SHEN Y F，et al. The clinical efficacy and safety of TACE combined with apatinib for advanced hepatocellular carcinoma：a propensity score matching analysis[J]. Indian J Cancer，2024，61（2）：390-395.
LU W，JIN X L，YANG C，et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma：a single-center randomized controlled trial[J]. Cancer Biol Ther，2017，18（6）：433-438.
何苗，曹佐锋，涂福平. TACE联合阿帕替尼治疗肝细胞肝癌的效果及对血压水平的影响[J]. 中国医学创新，2020，17（34）：81-84.
HE M，CAO Z F，TU F P. TACE combined with apatinib in the treatment of hepatocellular carcinoma and its effect on blood pressure level[J]. Med Innov China，2020，17（34）：81-84.
蒲嘉骐，廖运国，邓丹. TACE联合阿帕替尼治疗原发性肝癌的临床效果及对免疫功能的影响[J]. 现代医用影像学，2019，28（12）：2599-2601.
PU J Q，LIAO Y G，DENG D. Clinical effect of TACE combined with apatinib in the treatment of primary liver cancer and its effect on immune function[J]. Mod Med Imageol，2019，28（12）：2599-2601.
李威，满文玲，郭欢庆，等. TACE联合甲磺酸阿帕替尼治疗中晚期肝癌的临床研究[J]. 肿瘤药学，2017，7（1）：74-78.
LI W，MAN W L，GUO H Q，et al. Clinical research of apatinib with transcatheter arterial chemoembolization in treatment of advanced hepatocellular carcinoma[J]. Anti Tumor Pharm，2017，7（1）：74-78.
翁志成，彭建扬，吴伟达，等. 阿帕替尼联合S-TACE治疗中晚期原发性肝癌的疗效及安全性评价[J]. 癌症进展，2019，17（22）：2666-2669.
WENG Z C，PENG J Y，WU W D，et al. Evaluation of the efficacy and safety of combined therapy using apatinib and S-TACE as the treatment for patients with advanced hepatocellular carcinomas[J]. Oncol Prog，2019，17（22）：2666-2669.
黎莹，杨冬阳，赖晓嵘，等. 阿帕替尼联合TACE对肝癌患者AFP、VEGF和CEA的影响[J]. 肝脏，2018，23（5）：426-430.
LI Y，YANG D Y，LAI X R，et al. Effects of apatinib combined with TACE on AFP，VEGF and CEA in patients with liver cancer[J]. Chin Hepatol，2018，23（5）：426-430.
凌冰，韩绪生，杨勇，等. 阿帕替尼联合TACE治疗肝癌疗效及对患者血管内皮生长因子和甲胎蛋白的影响[J]. 现代消化及介入诊疗，2020，25（12）：1585-1590.
LING B，HAN X S，YANG Y，et al. Curative effect of apatinib combined with TACE on hepatic carcinoma and their influences on vascular endothelial growth factor and alpha-fetoprotein[J]. Mod Dig Interv，2020，25（12）：1585-1590.
曾筱怡. 阿帕替尼联合TACE治疗原发性肝癌的临床研究[J]. 基层医学论坛，2018，22（11）：1442-1444.
ZENG X Y. Apatinib combined with TACE in the treatment of primary liver cancer[J]. Med Forum，2018，22（11）：1442-1444.
陈巧辉，陈德志，王琦，等. 阿帕替尼联合肝动脉化疗栓塞术治疗中晚期肝癌的临床效果及安全性[J]. 临床合理用药杂志，2021，14（32）：1-3，6.
CHEN Q H，CHEN D Z，WANG Q，et al. Clinical effect and safety evaluation of apatinib combined with TACE in the treatment of advanced liver cancer[J]. Chin J Clin Ration Drug Use，2021，14（32）：1-3，6.
李鹏鑫.阿帕替尼联合肝动脉化疗栓塞术治疗肝癌的效果分析[J].中国社区医师，2023，39（32）：70-72.
LI P X.Effect analysis of apatinib combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma[J].Chin Comm Doct，2023，39（32）：70-72.
梁赟.阿帕替尼联合肝动脉介入化疗栓塞术治疗原发性肝癌的疗效分析[J/OL].现代医学与健康研究电子杂志，2023，7（8）：7-9[2024-05-31].http：//xdyx.bjzzcb.com/xdyx/article/abstract/202308003?sthttp://xdyx.bjzzcb.com/xdyx/article/abstract/202308003?st＝article_issue.DOI：10.3969/j.issn.2096-3718.2023.08.003http://dx.doi.org/10.3969/j.issn.2096-3718.2023.08.003.
LIANG Y.Analysis of the efficacy of apatinib combined with transarterial interventional chemotherapy and embolization in the treatment of primary liver cancer[J/OL]. Modern Med Health Res Electron J，2023，7（8）：7-9[2024-05-31].http：//xdyx.bjzzcb.com/xdyx/article/abstract/2023-08003?sthttp://xdyx.bjzzcb.com/xdyx/article/abstract/2023-08003?st＝article_issue.DOI：10.3969/j.issn.2096-3718.2023.08.003http://dx.doi.org/10.3969/j.issn.2096-3718.2023.08.003.
曾广源，吴龚丽莉，郑文，等.阿帕替尼片联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床研究[J].中国临床药理学杂志，2018，34（23）：2693-2696.
ZENG G Y，WU G L L，ZHENG W，et al.Clinical trial of apatinib tablets combined with transcatheter arterial chemoembolization in the treatment of advanced primary liver cancer [J]. Chin J Clin Pharmacol，2018，34（23）：2693-2696.
黄文薮，郭永建，黄敬君，等. 肝动脉化疗栓塞联合阿帕替尼治疗原发性肝癌的安全性和有效性分析[J/OL]. 中华介入放射学电子杂志，2020，8（3）：247-251[2024-05-31].https：//zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2020.03.012https://zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2020.03.012.
HUANG W S，GUO Y J，HUANG J J，et al. Analysis of safety and efficacy of hepatic artery chemoembolization combined with apatinib in the treatment of hepatocellular carcinoma[J/OL]. Chin J Interv Radiol（Electron Ed），2020，8（3）：247-251[2024-05-31].https：//zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2020.03.012https://zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2020.03.012.
周杰斌，李倩. 肝动脉化疗栓塞术联合阿帕替尼治疗肝癌的效果及对免疫功能的影响[J]. 中外医学研究，2021，19（26）：25-27.
ZHOU J B，LI Q. Efficacy of transcatheter arterial chemoembolization combined with apatinib in the treatment of liver cancer and its effect on immune function[J]. Chin Foreign Med Res，2021，19（26）：25-27.
隋永博，陈金玲，张重阳，等. 肝动脉化疗栓塞术联合阿帕替尼治疗中晚期肝癌的临床观察[J]. 中西医结合肝病杂志，2024，34（2）：123-125.
SUI Y B，CHEN J L，ZHANG C Y，et al. Clinical observation of transcatheter arterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma[J]. Chin J Integr Tradit West Med Liver Dis，2024，34（2）：123-125.
黄锐，姚立正，李文会，等. 肝动脉化疗栓塞术联合甲磺酸阿帕替尼片治疗中晚期肝癌的疗效及安全性评价[J]. 肿瘤，2018，38（10）：965-972.
HUANG R，YAO L Z，LI W H，et al. Efficacy and safety of TACE combined with apatinib mesylate tablets in the treatment of intermediate and advanced hepatoma[J]. Tumor，2018，38（10）：965-972.
杨庆，潘松松，施昌盛，等. 甲磺酸阿帕替尼联合TACE治疗中晚期肝癌的效果及对患者血清VEGF和MMP-9的影响[J]. 中华介入放射学电子杂志，2019，7（2）：111-116[2024-05-31]. https：//zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2019.02.005https://zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2019.02.005.
YANG Q，PAN S S，SHI C S，et al. Effect of apatinib mesylate combined with TACE in treatment of advanced hepatocellular carcinoma and its influence on serum levels of VEGF and MMP-9[J]. Chin J Interv Radiol （Electron Ed），2019，7（2）：111-116[2024-05-31]. https：//zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2019.02.005https://zhjrfsxdzzz.cma-cmc.com.cn/CN/10.3877/cma.j.issn.2095-5782.2019.02.005.
蔡争，宋建涛，饶航，等.甲磺酸阿帕替尼片联合肝动脉化疗栓塞治疗不可切除肝细胞肝癌患者的临床研究[J].中国临床药理学杂志，2020，36（23）：3903-3906.
CAI Z，SONG J T，RAO H，et al.Clinical study of metha-nesulfonate apatinib tablets combined with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. Chin J Clin Pharmacol，2020，36（23）：3903-3906.
朱青，段旭华，张延藏.经导管肝动脉化疗栓塞联合阿帕替尼治疗原发性肝癌患者的疗效观察及对肝功能及甲胎蛋白的影响[J].医药论坛杂志，2023，44（13）：1-4.
ZHU Q，DUAN X H，ZHANG Y Z.Clinical observation of transcatheter arterial chemoembolization combined with apatinib in the treatment of patients with primary liver cancer and its effect on liver function and serum alpha-fetoprotein[J]. J Med Forum，2023，44（13）：1-4.
马萍，周元敏，盖云竹，等. TACE联合仑伐替尼治疗中晚期肝癌的临床疗效[J]. 系统医学，2022，7（24）：173-177.
MA P，ZHOU Y M，GAI Y Z，et al. Clinical efficacy of TACE combined with lenvatinib in the treatment of intermediate to advanced hepatocellular carcinoma[J]. Syst Med，2022，7（24）：173-177.
刘波，钟明艳. 甲磺酸仑伐替尼联合TACE治疗原发性肝癌的临床研究[J]. 江西医药，2023，58（11）：1282-1285.
LIU B，ZHONG M Y. Clinical study of ranvartinib mesylate combined with TACE in the treatment of primary liver cancer[J]. Jiangxi Med J，2023，58（11）：1282-1285.
张凤琦，翁凌凌. 仑伐替尼联合肝动脉化疗栓塞术对中晚期肝癌患者的影响[J]. 中外医学研究，2022，20（31）：33-37.
ZHANG F Q，WENG L L. Effect of lenvatinib combined with transcatheter arterial chemoembolization on patients with advanced liver cancer[J]. Chin Foreign Med Res，2022，20（31）：33-37.
XIE Q Y，HUANG L P，GAO F W，et al. Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor[J]. Front Pharmacol，2022，13：965770.
王闯胜，朱培欣，石佳. 经导管动脉化疗栓塞术联合仑伐替尼或多纳非尼靶向治疗中晚期肝癌的效果及安全性对比研究[J]. 中国合理用药探索，2023，20（9）：44-50.
WANG C S，ZHU P X，SHI J. A comparative study on the efficacy and safety of transcatheter arterial chemoembolization combined with lenvatinib or donafenib in targeted therapy for liver cancer in intermediate to advanced stage[J]. Chin J Ration Drug Use，2023，20（9）：44-50.
KUDO M，HAN G H，FINN R S，et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma：a randomized phase Ⅲ trial[J]. Hepatology，2014，60（5）：1697-1707.
KUDO M，CHENG A L，PARK J W，et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma（ORIENTAL）：a randomised，double-blind，placebo-controlled，multicentre，phase 3 study[J]. Lancet Gastroenterol Hepatol，2018，3（1）：37-46.
常祖宽，王晓伟，马文芳，等.TACE联合阿帕替尼对不可手术切除晚期肝癌患者血清Caspase-8、VEGF水平的影响[J].黑龙江医药科学，2020，43（6）：157-158.
CHANG Z K，WANG X W，MA W F，et al.The effect of TACE combined with apatinib on serum levels of caspase-8 and VEGF in patients with unresectable advanced liver cancer[J]. Heilongjiang Med Pharm，2020，43（6）：157-158.
MI Y J，LIANG Y J，HUANG H B，et al. Apatinib（YN968D1）reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters[J]. Cancer Res，2010，70（20）：7981-7991.
TONG X Z，WANG F，LIANG S，et al. Apatinib（YN968D1）enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol，2012，83（5）：586-597.
CHEN R S，IELASI L，CARLO A D，et al. Donafenib in hepatocellular carcinoma[J]. Drugs Today，2023，59（2）：83-90.
李苏，秦叔逵. 氘代药物及其在抗肿瘤新药研发中的应用前景[J]. 临床肿瘤学杂志，2020，25（12）：1138-1143.
LI S，QIN S K. Deuterated drugs and their application prospects in the development of new anti-tumor drugs[J]. Chin Clin Oncol，2020，25（12）：1138-1143.
QIN S K，BI F，GU S Z，et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma：a randomized，open-label，parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol，2021，39（27）：3002-3011.
佘明金，孙登群. 晚期肝癌一线治疗的研究进展[J]. 癌症进展，2024，22（4）：362-367，384.
SHE M J，SUN D Q. Research progress in first-line treatment of advanced liver cancer[J]. Oncol Prog，2024，22（4）：362-367，384.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.